期刊文献+

乳腺浸润性导管癌分子亚型与临床病理特征及预后的关系 被引量:20

Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis
原文传递
导出
摘要 目的 检测乳腺浸润性导管癌的临床病理特征及特定蛋白的表达情况,对其进行分型,探讨各哑型与预后的关系.方法 采用免疫组织化学EnVision法检测128例浸润性导管癌ER、PR、HER2和CK5/6的表达,参考文献报道的免疫分型方法 对其分型,并对HER2过表达型9例进行FISH检测.结果 ER、PR、HER2和CKS/6在本组128例浸润性导管癌中的阳性表达率分别为67%(86/128)、45%(58/128)、27%(34/128)和27%(34/128),并将128例分为5种免疫哑型,管腔A型55%(70/128),管腔B型20%(25/128),HER2过表达型7%(9/128),基底细胞样型10%(13/128),无法分类型8%(11/128).FISH检测HER2过表达型9例均为HER2基因扩增.各分子亚型间预后差异具有统计学意义,管腔A型预后最好,基底细胞型预后较差.多因素分析,乳腺癌临床分期和免疫分型是独立的预后因素.月经状态在乳腺癌各免疫亚型中的分布差异有统计学意义.结论 通过检测ER、PR、HER2和CK5/6的表达可以将乳腺浸润性导管癌分成具有不同生物学行为的5个免疫亚型,对于评估预后,指导治疗具有一定的意义. Objectives This study try to subclassify breast cancer into different prognostic subgroups according to immunohistochemical algorithm and discuss the relationship between subtypes and biological and clinical behavior and prognosis. Methods One hundred and twenty-eight cases of infiltrative ductal carcinoma were studied using immunohistochemical staining with an antibody panel of ER, PR, HER2 and CK5/6 and subclassified referring to previous reports, and the 9 cases of HER2 positive subtype were tested using FISH. Results The expression of ER, PR, HER2, and CK5/6 was detected in 67% ,45% ,27% and 27% cases , respectively. All cases were subclassified into five subgroups, with luminal A (55%), luminal B (20%) , HER2 positive (7%) , basal-like (10%) and unclassied cases (8%). Nine HER2 positive cases all showed amplification of HER2 gene. It was demonstrated that the luminal A group was associated with the best prognosis but the basal-like group worst by univariate analysis. Multivariate analysis demonstrated that both the clinical stage and immunohistochemical subtypes of tumor were related to overall survival. Menses status were different among these subtypes. Conclusion According to the expression of ER, PR, HER2 and CK5/6, infiltrative ductal carcinoma could be subclassified into five subgroups with different biological features and outcome, having a role in evaluating the prognosis and guiding the clinical treatment.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2010年第6期372-376,共5页 Chinese Journal of Pathology
关键词 乳腺肿瘤 导管 乳腺 免疫表型分型 无病生存 Breast neoplasms Carcinoma,ductal,breast Immunophenotyping Disease-free survival
  • 相关文献

参考文献19

  • 1Sotiriou C,Neo SY,McShane LM,et al.Breast cancer classification and prognosis based on gene expression profiles from a population-based study.Proc Natl Acad Sci U S A,2003,100(18):10393-10398.
  • 2Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295(21):2492-2502.
  • 3Jacquemier J,Ginestier C,Rougemont J,et al.Protein expression profiling identifies subclasses of breast cancer and predicts prognosis.Cancer Res,2005,65(3):767-779.
  • 4Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Ann Oncol,2005,16(10):1569-1583.
  • 5唐平,魏兵,David G. Hicks,Kristin Skinner,步宏.乳腺癌的分子分类及其临床应用[J].中华病理学杂志,2009,38(1):13-17. 被引量:24
  • 6皋岚湘,杨光之,丁华野,李琳.基底细胞样型浸润性乳腺癌病理形态观察[J].中华病理学杂志,2008,37(2):83-87. 被引量:36
  • 7Hammock L,Lewis M,Phillips C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34(10):1043-1047.
  • 8袁中玉,王树森,朱美琴,郑磊,罗文标,周中梅,管忠震.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461. 被引量:55
  • 9陈小松,马传栋,陈灿铭,杨文涛,陆洪芬,周晓燕,柳光宇,狄根红,吴炅,陆劲松,韩企夏,邵志敏,沈镇宙,沈坤炜.乳腺癌分子分型与预后关系的研究[J].中华外科杂志,2008,46(18):1400-1403. 被引量:14
  • 10Sφrlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Nad Acad Sci U S A,2003,100(14):8418-8423.

二级参考文献145

  • 1杨丽芳,宋三泰,李晓兵,江泽飞,刘晓晴,马维娜,乔西平,郭斯启.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,28(4):294-297. 被引量:11
  • 2余科达,狄根红,吴炅,陆劲松,沈坤炜,沈镇宙,邵志敏.ER(-)PR(+)乳腺癌辅助内分泌治疗的疗效[J].中国癌症杂志,2006,16(12):1011-1015. 被引量:13
  • 3赵卫红,徐兵河,张频,李青,赵龙妹,孙燕.乳腺癌合并脉管瘤栓的临床病理特点及预后因素分析[J].中华肿瘤杂志,2007,29(2):137-140. 被引量:14
  • 4步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 5Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin : three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 2005, 447(4):688-694.
  • 6Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res, 2006, 8(5) :R58.
  • 7Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797) :747-752.
  • 8Sφrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nail Aead Sci U S A, 2001, 98(19) :10869-10874.
  • 9Sφrlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Nail Acad Sci U S A, 2003, 100(14):8418-8423.
  • 10Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A, 2003,100(18):10393-10398.

共引文献187

同被引文献158

引证文献20

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部